Hydrocortisone succinate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Hydrocortisone succinate
Accession Number
DB14545
Type
Small Molecule
Groups
Approved
Description
Not Available
Structure
Thumb
Synonyms
  • Cortisol 21-(hydrogen succinate)
  • Cortisol succinate
  • Hydrocortisone hemisuccinate anhydrous
  • Hydrocortisone hydrogen succinate
  • Hydroxycortisone succinate
Product Ingredients
IngredientUNIICASInChI Key
Hydrocortisone sodium succinate50LQB69S1Z125-04-2HHZQLQREDATOBM-CODXZCKSSA-M
Hydrocortisone succinate monohydrateLIU00Z1Z8483784-20-7AFLWPAGYTPJSEY-CODXZCKSSA-N
Active Moieties
NameKindUNIICASInChI Key
HydrocortisoneunknownWI4X0X7BPJ50-23-7JYGXADMDTFJGBT-VWUMJDOOSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Solu-CortefInjection, powder, for solution100 mg/2mLIntramuscular; IntravenousPhysicians Total Care, Inc.1955-04-272013-06-01Us
Solu-CortefInjection, powder, for solution100 mg/2mLIntramuscular; IntravenousPharmacia & Upjohn Inc1955-04-27Not applicableUs
Solu-cortefInjection, powder, for solution100 mg/2mLIntramuscular; IntravenousHF Acquisition Co. LLC, DBA HealthFirst2018-09-03Not applicableUs
Solu-CortefInjection, powder, for solution500 mg/4mLIntramuscular; IntravenousPharmacia & Upjohn Inc1955-04-27Not applicableUs
Solu-cortefInjection, powder, for solution250 mg/2mLIntramuscular; IntravascularPharmacia & Upjohn Inc1980-04-272014-10-01Us
Solu-cortefInjection, powder, for solution1000 mg/8mLIntramuscular; IntravascularPharmacia & Upjohn Inc1980-04-272014-05-01Us
Solu-cortefInjection, powder, for solution100 mg/2mLIntramuscular; IntravascularCardinal Health1955-04-272015-02-28Us
Solu-CortefInjection, powder, for solution100 mg/2mLIntramuscular; IntravenousCardinal Health1955-04-27Not applicableUs
Solu-cortefInjection, powder, for solution100 mg/2mLIntramuscular; IntravascularPharmacia & Upjohn Inc1980-04-272015-02-01Us
Solu-CortefInjection, powder, for solution250 mg/2mLIntramuscular; IntravenousPharmacia & Upjohn Inc1955-04-27Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
A-hydrocortInjection, powder, lyophilized, for solution100 mg/2mLIntramuscular; IntravenousHospira, Inc.2006-12-142010-07-01Us
Categories
UNII
IHV1VP592V
CAS number
2203-97-6
Weight
Average: 462.539
Monoisotopic: 462.225368055
Chemical Formula
C25H34O8
InChI Key
VWQWXZAWFPZJDA-CGVGKPPMSA-N
InChI
InChI=1S/C25H34O8/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30/h11,16-18,22,27,32H,3-10,12-13H2,1-2H3,(H,29,30)/t16-,17-,18-,22+,23-,24-,25-/m0/s1
IUPAC Name
4-{2-[(1R,3aS,3bS,9aR,9bS,10S,11aS)-1,10-dihydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethoxy}-4-oxobutanoic acid
SMILES
[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be increased when combined with Hydrocortisone succinate.
(S)-WarfarinThe metabolism of (S)-Warfarin can be increased when combined with Hydrocortisone succinate.
1-TestosteroneThe risk or severity of edema formation can be increased when 1-Testosterone is combined with Hydrocortisone succinate.
1,10-PhenanthrolineThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Hydrocortisone succinate.
16-BromoepiandrosteroneThe risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Hydrocortisone succinate.
19-norandrostenedioneThe risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Hydrocortisone succinate.
1alpha-Hydroxyvitamin D5The therapeutic efficacy of 1alpha-Hydroxyvitamin D5 can be decreased when used in combination with Hydrocortisone succinate.
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Hydrocortisone succinate.
3,5-diiodothyropropionic acidThe metabolism of 3,5-diiodothyropropionic acid can be increased when combined with Hydrocortisone succinate.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be increased when combined with Hydrocortisone succinate.
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D01442
ChemSpider
15760
BindingDB
50016931
ChEBI
31677
ChEMBL
CHEMBL977
Wikipedia
Hydrocortisone_hemisuccinate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingBasic ScienceSleep Restriction1
4CompletedTreatmentShock, Septic1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous100 mg/2mL
Injection, powder, for solutionIntramuscular; Intravascular100 mg/2mL
Injection, powder, for solutionIntramuscular; Intravascular1000 mg/8mL
Injection, powder, for solutionIntramuscular; Intravascular250 mg/2mL
Injection, powder, for solutionIntramuscular; Intravascular500 mg/4mL
Injection, powder, for solutionIntramuscular; Intravenous100 mg/2mL
Injection, powder, for solutionIntramuscular; Intravenous1000 mg/8mL
Injection, powder, for solutionIntramuscular; Intravenous250 mg/2mL
Injection, powder, for solutionIntramuscular; Intravenous500 mg/4mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0653 mg/mLALOGPS
logP2.17ALOGPS
logP1.54ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)3.66ChemAxon
pKa (Strongest Basic)-2.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area138.2 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity117.44 m3·mol-1ChemAxon
Polarizability48.68 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Yamamoto N, Tamura T, Kamiya Y, Sekine I, Kunitoh H, Saijo N: Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol. 2000 Jun;18(11):2301-8. doi: 10.1200/JCO.2000.18.11.2301. [PubMed:10829051]
  3. Litt J. (2016). Litt's Drug eruption & reaction manual (22nd ed.). CRC Press LLc.
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Bauersachs J, Christ M, Ertl G, Michaelis UR, Fisslthaler B, Busse R, Fleming I: Cytochrome P450 2C expression and EDHF-mediated relaxation in porcine coronary arteries is increased by cortisol. Cardiovasc Res. 2002 Jun;54(3):669-75. [PubMed:12031713]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid 11-beta-monooxygenase activity
Specific Function
Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochro...
Gene Name
CYP11B1
Uniprot ID
P15538
Uniprot Name
Cytochrome P450 11B1, mitochondrial
Molecular Weight
57572.44 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid 11-beta-monooxygenase activity
Specific Function
Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone.
Gene Name
CYP11B2
Uniprot ID
P19099
Uniprot Name
Cytochrome P450 11B2, mitochondrial
Molecular Weight
57559.62 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on July 12, 2018 15:25 / Updated on November 02, 2018 09:16